BTK degrader patent BGB-16673: PROTAC linker analysis

Why BTK Degraders Represent a Strategic Shift Beyond BTK Inhibition

BTK degraders like BGB-16673 represent a mechanistic departure from conventional BTK inhibitors: rather than blocking kinase activity, they recruit the cell’s ubiquitin-proteasome system to physically eliminate the BTK protein. This distinction matters because resistance to covalent BTK inhibitors — most commonly arising from the C481S mutation — does not confer resistance to degradation-based approaches that can engage BTK through non-covalent contacts and destroy the entire protein. For IP professionals and R&D leaders monitoring the competitive landscape, this mechanistic divergence also defines a distinct patent space.

The PROTAC (Proteolysis Targeting Chimera) modality requires a bifunctional molecular architecture: a warhead that binds the target protein (BTK), a chemical linker, and a ligand that recruits an E3 ubiquitin ligase. The ternary complex formed between the target, the PROTAC, and the E3 ligase triggers polyubiquitination of BTK, marking it for proteasomal degradation. According to WIPO, targeted protein degradation patent filings have grown substantially since 2019, reflecting the pharmaceutical industry’s strategic investment in this modality.

The clinical and commercial rationale for BeiGene’s BTK degrader program — developed under BeOne Medicines Ltd., a BeiGene subsidiary — is grounded in the unmet need of patients who have progressed on ibrutinib or second-generation covalent inhibitors such as zanubrutinib (BeiGene’s own BTK inhibitor, Brukinsa). BGB-16673 is designed to address this population by deploying a degradation mechanism that does not require covalent engagement of C481.

Mapping the BeiGene BTK Degrader Patent Family

BeiGene’s BTK degrader intellectual property is distributed across a multi-jurisdictional patent family, with the core inventive claims covering bifunctional compounds that conjugate BTK inhibitor moieties to E3 ligase ligands. The identified family members are: US20230167118A1 (published 1 June 2023), US20230322761A1 (published 12 October 2023), the granted US12521440B2 (published 13 January 2026), and CN116981675A (the Chinese equivalent). All are titled “Degradation of Bruton’s tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use.”

The note regarding patent number WO2023056241A1 is important for practitioners conducting freedom-to-operate or landscape analyses: this number, as identified in patent database searches, corresponds to a Qualcomm telecommunications patent rather than a BeiGene pharmaceutical patent. IP professionals should verify patent numbers against BeiGene’s official publications, SEC filings, or ClinicalTrials.gov entries for BGB-16673 before relying on any specific WO number. The correct BeiGene BTK degrader filings are the US and CN family members identified above.

PROTAC Architecture: Linker Design and E3 Ligase Recruitment Strategy

BeiGene’s BTK degrader patents describe bifunctional PROTAC compounds that link a BTK inhibitor moiety to an E3 ligase ligand via a chemical linker — the three-component architecture that defines the PROTAC modality. The patent titles explicitly reference “conjugation of BTK inhibitors with E3 ligase ligand,” confirming the bifunctional design. Detailed compound structures, linker chemistry, and E3 ligase identity are contained in the Examples sections and compound tables of the full patent texts, particularly US20230167118A1 and the granted US12521440B2.

In the broader PROTAC field, E3 ligase selection is a critical determinant of tissue-specific degradation efficiency, tolerability, and resistance potential. The two most widely used E3 ligase systems in clinical-stage PROTACs are cereblon (CRBN) — recruited by thalidomide-derived IMiD ligands — and VHL (von Hippel-Lindau), recruited by hydroxyproline-based ligands. As reported by Nature and the broader PROTAC literature, cereblon-based degraders have dominated early clinical development due to the established safety profile of IMiD scaffolds. The BeiGene patent family’s reference to “E3 ligase ligand” without further specification in available abstracts means the precise E3 ligase identity must be confirmed from the full patent text.

“BeiGene’s BTK degrader patents describe bifunctional PROTAC compounds linking BTK inhibitor moieties with E3 ligase ligands — a design that enables proteasomal elimination of BTK rather than mere inhibition of its kinase activity.”

Linker architecture is equally consequential for PROTAC performance. Linker length, rigidity, and chemical composition influence the geometry of the ternary complex, which in turn determines the efficiency of BTK ubiquitination. Shorter, more rigid linkers can improve selectivity but may constrain the conformational flexibility needed for productive ternary complex formation. PEG-based (polyethylene glycol) linkers improve aqueous solubility and are frequently employed when molecular weight and cell permeability must be balanced. Alkyl and piperazine-containing linkers are also common in BTK degrader SAR series. The specific linker variants explored across BGB-16673’s analog series — and the structural features that differentiated the lead compound — are documented in the compound tables and biological data sections of the full patent texts.

BGB-16673 as the Recommended Clinical Candidate: Phase 3 Development

BGB-16673 (Catadegbrutinib) has advanced to Phase 3 clinical development — the most advanced stage of any BTK-targeting PROTAC in the public domain as of mid-2025. Its indications span chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and B-cell malignancies, developed by BeOne Medicines Ltd., the BeiGene subsidiary responsible for the program. The progression to Phase 3 from a PROTAC modality — historically challenged by issues of molecular weight, cell permeability, and oral bioavailability — represents a significant milestone for the targeted protein degradation field.

The selection of BGB-16673 as the recommended clinical compound from its analog series reflects a multi-parameter optimisation process typical of PROTAC drug discovery: balancing degradation potency (DC50), selectivity (Dmax — maximum degradation), pharmacokinetic properties, and tolerability. In patent practice, the Examples section of a compound patent typically enumerates dozens of analogs with their associated biological data, with the clinical candidate distinguished by a superior profile across these parameters. For BGB-16673, the specific structural features — including the precise BTK warhead scaffold, linker composition, and E3 ligase ligand — that confer its clinical differentiation are detailed in the BeiGene patent family.

The clinical context is also shaped by BeiGene’s existing BTK inhibitor franchise: zanubrutinib (Brukinsa) is an approved second-generation covalent BTK inhibitor. BGB-16673 is positioned to address patients who have progressed on covalent BTK inhibitors, where resistance mutations at C481 render covalent inhibitors ineffective. As noted by FDA guidance on oncology drug development, demonstrating activity in the ibrutinib-refractory setting is a key regulatory consideration for next-generation BTK-targeting agents.

What Patent Intelligence Reveals — and Where Gaps Remain

Patent intelligence on BGB-16673 confirms the core inventive framework — bifunctional PROTAC design, BTK inhibitor conjugation with an E3 ligase ligand, and a multi-jurisdictional filing strategy — but the granular structural and pharmacological data that practitioners most need (exact linker structures, DC50 tables, SAR comparisons across the analog series) resides in the full text of the patent documents rather than in abstracts or bibliographic records. This is a consistent feature of pharmaceutical compound patents: the claims define the scope, but the Examples section contains the scientific substance.

A further important note for patent intelligence practitioners: the patent number WO2023056241A1, as identified in patent database searches, corresponds to a Qualcomm telecommunications patent rather than a BeiGene pharmaceutical filing. This type of discrepancy — where a patent number circulates in secondary sources but does not match the expected assignee or subject matter — is a known challenge in pharmaceutical IP research. The correct approach is to verify patent numbers against primary sources: BeiGene’s official filings, SEC disclosures, or ClinicalTrials.gov entries for BGB-16673. The confirmed BeiGene BTK degrader family members are US20230167118A1, US20230322761A1, US12521440B2, and CN116981675A.

For competitive intelligence purposes, the granted status of US12521440B2 (published 13 January 2026) is particularly significant: granted patents provide enforceable claims and define the freedom-to-operate landscape for competitors developing BTK degraders. According to USPTO records, granted status means the claims have survived examination and represent the strongest form of IP protection available. Competitors and licensees should conduct claim-by-claim analysis of US12521440B2 to understand the scope of BeiGene’s protection around the PROTAC BTK degrader design space.

For R&D leaders and patent counsel, the recommended workflow for obtaining the complete structural and pharmacological picture of BGB-16673 is: (1) retrieve the full text of US20230167118A1 and US12521440B2 from EPO Espacenet or PatSnap Eureka; (2) navigate to the Examples section for compound tables, biological assay data, and DC50 values; (3) cross-reference with ClinicalTrials.gov entries for BGB-16673 to identify which compound number in the patent series corresponds to the clinical candidate; and (4) conduct claim mapping against US12521440B2 for freedom-to-operate purposes.